Continue reading this on our app for a better experience

Open in App
Home Capital Broker's Calls

Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB

Michelle Zhu
Michelle Zhu • 2 min read
Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB
SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.